By PPN News Staff
The FDA approved etanercept-szzs (Erelzi, Sandoz) for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept, Amgen), which was originally licensed in 1998.
Administered by injection, Erelzi received approval for all the indications of the reference product:
- moderate to severe rheumatoid arthritis, either as a stand-alone therapy or in combination with methotrexate (MTX);
- moderate to severe polyarticular juvenile idiopathic arthritis in patients 2 years of